Investing
Top Analyst Upgrades and Downgrades: Crocs, Gap, GW Pharma, Lowe's, Merck, Nio, Palo Alto, Phillips 66, Starbucks, Vital Farms and More
August 25, 2020 9:06 am
Last Updated: August 25, 2020 9:22 am
Stocks surged on Monday with the S&P 500 hitting another all-time high. The indexes were trading higher on Tuesday, with average gains of about 0.5% in Dow Jones industrials and S&P 500 futures. The S&P 500 is now up well over 50% from the March panic selling lows, but with earnings season winding down many investors feel as though they may have missed out on the recovery rally. This is a time when investors should be considering new ideas for how to be positioned in the rest of 2020 and ahead of the election.
24/7 Wall St. reviews dozens of analyst research reports each day of the week in an effort to find new ideas for long-term investors and short-term traders alike. Some analyst reports cover stocks to buy, and others cover stocks to sell or avoid.
Remember that no single analyst call should ever be used as a basis to buy or sell a stock. Consensus analyst target data is from Refinitiv.
These are the top analyst upgrades, downgrades and initiations from Tuesday, August 25, 2020.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) was started with an Outperform rating and a $65 target price (versus a $38.00 prior close) at Raymond James.
arGEN-X S.E. (NASDAQ: ARGX) was started as Outperform with a $257 target price (versus a $232.77 close) at Raymond James.
Builders FirstSource Inc. (NASDAQ: BLDR) was reiterated as Buy and its target was raised to $33 from $27 (versus a $28.62 close) at Truist Securities.
Crocs Inc. (NASDAQ: CROX) was raised to Buy from Neutral and its target price was raised to $46 from $35 (versus a $39.34 close) at B. Riley FBR.
Forte Biosciences Inc. (NASDAQ: FBRX) was started as Buy and a $70 target price (versus a $24.70 close) at Truist Securities.
Galapagos N.V. (NASDAQ: GLPG) was downgraded to Hold from Buy at Jefferies.
Gap Inc. (NYSE: GPS) was raised to Buy from Neutral and its target price was raised to $24 from $12 (versus a $15.50 close) at Citigroup.
Global Blood Therapeutics Inc. (NASDAQ: GBT) was started as Outperform and its price target was set at $115 (versus a $62.61 close) at Raymond James.
GW Pharmaceuticals PLC (NASDAQ: GWPH) was started with a Market Perform rating at Raymond James.
L Brands Inc. (NYSE: LB) was raised to Buy from Neutral with a $40 target price (versus a $29.63 close) at MKM Partners.
Lowe’s Companies Inc. (NYSE: LOW) was reiterated as Overweight and its price target was raised to $190 from $160 (versus a $165.63 close) at Morgan Stanley.
Merck & Co. Inc. (NYSE: MRK) was reiterated as Outperform and its target price was raised to $100 from $95 (versus an $85.42 close) at SVB Leerink.
Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) was downgraded to Neutral from Buy at H.C. Wainwright.
NeoPhotonics Corp. (NASDAQ: NPTN) was downgraded to Underperform from Market Perform at Raymond James.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Editors' Picks
